Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Combination Bisphosphonate and Anti-Angiogenesis Therapy with Pamidronate and Thalidomide
This study is currently recruiting patients.
Sponsored by: | University of Arkansas
Celgene Corporation
|
---|---|
Information provided by: | University of Arkansas |
Purpose
The purpose of this research is to study how helpful the combination of thalidomide and Pamidronate is in controlling multiple myeloma and to study any side effects that may be experienced.
Condition | Treatment or Intervention | Phase |
---|---|---|
Multiple Myeloma |
Drug: Pamidronate Drug: Thalidomide |
Phase II |
MedlinePlus related topics: Multiple Myeloma
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: UARK 99-016, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy with Pamidronate and Thalidomide in Patients with Multiple Myeloma and Poor Hematopoietic Stem Cell Reserve
Expected Total Enrollment: 20
Study start: March 1998
Recently, laboratory research found that thalidomide can inhibit the formation of new blood vessels that are necessary for the growth and spread of cancer. In order to grow and increase in size, tumors require new blood vessels to supply them with the necessary blood to grow. If we can prevent these new blood vessels feeding the tumor from being formed by using thalidomide we might slow or stop the growth of the tumor. This concept is called “anti-angiogenesis”. It is hoped that thalidomide will slow or stop the growth myeloma. However, it cannot be guaranteed that you will benefit if you take part in this study. The treatment you receive may even be harmful.
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Exclusion Criteria:
Location and Contact Information
More Information
Myeloma Institute for Research & Therapy website
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |